down arrow

Concord Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE858L01010
  • NSEID:
  • BSEID: 538965
INR
31.87
0.87 (2.81%)
BSENSE

Apr 11, 12:51 PM

BSE+NSE Vol: 1.18 k

Click here to access the older version
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Divi's Lab.
Cipla
Sun Pharma.Inds.
Torrent Pharma
Ishita Drugs
Mankind Pharma
Concord Drugs
Colinz Labs
Zenith Health
Omkar Pharmachem
Medicamen
Why is Concord Drugs Ltd ?
1
Weak Long Term Fundamental Strength with a -6.24% CAGR growth in Operating Profits over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 5.10 times
  • The company has been able to generate a Return on Equity (avg) of 2.50% signifying low profitability per unit of shareholders funds
2
Flat results in Dec 24
  • NET SALES(Q) At Rs 10.80 cr has Fallen at -15.49 %
3
Stock is technically in a Bearish range
  • The technical trend has deteriorated from Mildly Bearish on 17-Mar-25 and has generated -6.13% returns since then
  • Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST
4
Below par performance in long term as well as near term
  • Along with generating -17.10% returns in the last 1 year, the stock has also underperformed BSE 500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Concord Drugs for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Concord Drugs
-17.8%
-0.33
51.72%
SENSEX
0.45%
0.03
14.48%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-3.78%
EBIT Growth (5y)
-6.24%
EBIT to Interest (avg)
1.36
Debt to EBITDA (avg)
3.16
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.28
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.47%
ROE (avg)
2.50%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
33
Price to Book Value
0.92
EV to EBIT
25.15
EV to EBITDA
14.59
EV to Capital Employed
0.95
EV to Sales
0.99
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
2.29%
ROE (Latest)
-1.51%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company
PBDIT(Q)

Highest at Rs 1.39 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 12.87%

PBT LESS OI(Q)

Highest at Rs 0.53 cr.

PAT(Q)

Highest at Rs 0.23 cr.

EPS(Q)

Highest at Rs 0.23

-3What is not working for the Company
NET SALES(Q)

At Rs 10.80 cr has Fallen at -15.49 %

Loading Valuation Snapshot...
Here's what is working for Concord Drugs
Operating Profit (PBDIT) - Quarterly
Highest at Rs 1.39 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 12.87%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 0.53 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 0.23 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 0.23
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Concord Drugs
Net Sales - Quarterly
At Rs 10.80 cr has Fallen at -15.49 %
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (Rs Cr)

Net Sales - Quarterly
Lowest at Rs 10.80 cr
in the last five quarters
MOJO Watch
Near term sales trend is negative

Net Sales (Rs Cr)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."